|The following is our latest Fund Analyst Report for BlackRock LifePath Index (LIRKX). Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Not a Premium Member? Gain full access to our analyst reports and advanced tools immediately when you try Morningstar Premium free for 14 days.|
BlackRock LifePath Index's forward-thinking management team, research-intensive process, extremely low costs, and high-quality building blocks place this series among the industry's very best options. It continues to earn a Morningstar Analyst Rating of Gold.
BlackRock's history with target-date funds stretches back to the 1990s, but most importantly, the firm has remained steadfast in evolving its target-date options over the decades, often exploring new areas of research before peers. The firm's target-date glide path and asset-allocation research, led by Matt O'Hara since 2014, has led to some significant changes and unique aspects. Management’s active research agenda and its willingness to enact meaningful changes--including those that put it at odds with most peers--to improve participant outcomes give us confidence in the team staying at the forefront of the target-date industry over the long term.
Jason Kephart, CFA does not own shares in any of the securities mentioned above. Find out about Morningstar's editorial policies.